A month has gone by since the last earnings report for Merck (MRK). Shares have added about 3.9% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...

Everyone is talking about or using weight loss products. So, the government pounces. A batch of 17 drugs are on a list of ...

The negotiated prices for the Janumet franchise will take effect in 2027. Merck was the first of many drugmakers to sue the U.S. government in 2023 over the “sham” pricing negotiations ...

Merck (NYSE:MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting ...

Merck added that its drugs Janumet and Janumet XR were selected for the second round of negotiations, with those prices slated to take effect in January 2027. "The company expects that in 2026 ...